ClinicalTrials.gg
CompletedNCT02981342Updated Nov 20, 2019Results posted

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

A Phase 2 interventional study of Abemaciclib and LY3023414 in Pancreatic Ductal Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 32 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies testing gemcitabine in Pancreatic Neoplasms — 29 open to participants now, 44 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.

Enrollment
61st of 352
106 · median 37
Started
2017
with 6 others
Phase 2
195 of 369
18 open now
Registered
286th of 369
by date
Lead sponsor
5 of 369
Eli Lilly and Company

Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 61st largest by enrollment of the 352 interventional ones that give a count, is one of 7 that started in 2017, is one of 195 in phase 2, and was the 286th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

29 of the 369 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies testing gemcitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma

Keywords

  • pancreatic cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of ductal adenocarcinoma of the pancreas.
  • disease with documented disease progression following previous treatment with at least one, but no more than 2 prior therapies, with one of the prior therapies having been either gemcitabine-based or fluoropyrimidine-based therapy. and/or adjuvant therapies for localized resectable or unresectable PDAC each count as a if multiagent chemotherapy regimens were administered (and neoadjuvant regimen was different than adjuvant regimen) and if the participant progressed with metastatic disease while taking or within 6 months of completion of (neo)adjuvant therapy.
  • per (RECIST) 1.1.
  • (ECOG) performance status of 0 or 1.
  • Participant for whom treatment with monotherapy chemotherapy such as gemcitabine or capecitabine is a reasonable choice.
  • Discontinued all prior treatment for cancer at least 14 days prior to initial dose of study treatment.
  • Adequate organ function.

    • allow (ALT) or aspartate aminotransferase (AST) up to 5x (ULN) if liver metastases.
    • allow up to 2.5 times ULN if elevation is not associated with other signs of liver toxicity or can be explained by mechanical obstruction - requires clinical research physician approval.

Exclusion criteria

Exclusion Criteria:

  • Have a personal history of any of the following conditions: syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Participants with controlled atrial fibrillation for >30 days prior to study treatment initiation are eligible.
  • Have insulin-dependent diabetes mellitus. Participants with type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained by oral anti-diabetics as documented by (HbA1c) \<7%.
  • Have symptomatic central nervous system . Screening of asymptomatic participants is not required for enrollment.
  • Have had major surgery within 7 days prior to initiation of study drug to allow for postoperative healing of the surgical wound and site(s).
  • Have previously received treatment with any cyclin-dependent kinase (CDK) 4 and 6 inhibitor or phosphatidylinositol 3-kinase (PI3K) and/or mammalian target of rapamycin (mTOR) inhibitor or have a known to any component of the products in this study.
  • Have a known hypersensitivity to investigator's choice of standard of care (gemcitabine or capecitabine).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Abemaciclib

    Abemaciclib given orally.

    Drug: Abemaciclib

  • Experimental
    Abemaciclib + LY3023414

    Abemaciclib given orally and LY3023414 given orally.

    Drug: Abemaciclib · Drug: LY3023414

  • Experimental
    Standard of Care (Gemcitabine or Capecitabine)

    Gemcitabine given intravenously (IV) OR capecitabine given orally.

    Drug: Gemcitabine · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)

    Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)

  2. Stage 2: Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization until first observation of objective progressive disease as defined by RECIST v1.1 or death from any cause, whichever comes first. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a patient does not have a complete baseline disease assessment, then the PFS time will be censored at the randomization date, regardless of whether or not objectively determined disease progression or death has been observed for the patient; otherwise, if a patient is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time will be censored at the last complete objective progression-free disease assessment date.

    Time frame: Baseline to Measured Progressive Disease or Death Due to Any Cause (Up to 6 Months)

Secondary outcomes

  1. Stage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR

    Objective response rate (ORR) is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Up to 6 Months)

  2. Stage 1: Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib and Its Metabolites (LSN2839567 (M2), LSN3106726 (M20))

    Mean steady state exposure was reported as measured by maximum observed plasma concentration (Cmax).

    Time frame: Cycle(C)1 Day(D)14: 0 hour(h),0.5h,1h,2h,4h,6h,8h post dose

  3. Stage 1: PK: Area Under the Curve (AUC) (AUC[Tau]) of LY3023414

    Time frame: Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)

  4. Stage 1: PK: Maximum Concentration (Cmax) at Steady State of LY3023414

    Time frame: Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)

  5. Stage 2: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD

    Time frame: Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)

  6. Stage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months

    Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD ≥6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

    Time frame: Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 6 Months)

  7. Stage 2: Duration of Response (DoR)

    Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 6 Months)

  8. Stage 2: Overall Survival (OS)

    OS duration is measured from the date of randomization to the date of death from any cause. for participants who is not known to have died as of the data-inclusion cutoff date, OS was censored at the last known alive date. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

    Time frame: Baseline to Death from Any Cause (Up to 10 Months)

  9. Stage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level

    No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

    Time frame: Baseline, 6 Months

  10. Stage 2: Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)

    mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, and enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours, and typical completion time for this instrument is less than 5 minutes. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

    Time frame: Baseline, 6 Months

  11. Stage 2: Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

    Time frame: Baseline, 6 Months

  12. Stage 1: PK: Steady State Trough Pre Dose Concentration of LY3023414

    Mean steady state exposure was reported by trough pre-dose plasma concentrations.

    Time frame: C2D1: 0h, C3D1: 0h, C4D1: 0h

  13. Stage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose

    Mean single dose exposure was reported by plasma concentrations collected approximately 2 hours post-dose.

    Time frame: C1D1: 2h Post dose

07

Results

Posted Jun 25, 2019
Limitations and caveats
Study was planned for stage 1 \& stage 2. Stage 2 did not occur, no participants were enrolled to stage 2;

Participant flow

Study was planned for stage 1 \& stage 2. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1. Completed participants are those who has CR, PR, SD, or PD and is off treatment.

Participant flow — Overall Study
Milestone150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in)200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Started7333333
Received at least one dose of study drug7323326
Completed7222019
Not completed0111314
Withdrew: Adverse event0001
Withdrew: Death0994
Withdrew: Withdrawal by subject0031
Withdrew: Study closed by sponsor0011
Withdrew: Randomized, never treated0107
Withdrew: Lost to follow-up0100

Outcome measures

PrimaryStage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)

Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)
Reported as:
Number · percentage of Participants
Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)
percentage of Participants200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)15.2 (2.9 to 27.4)12.1 (1.0 to 23.3)36.4 (20 to 52.8)
Statistical analysis
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Cochran-Mantel-Haenszel · p = 0.0495
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Cochran-Mantel-Haenszel · p = 0.0230
PrimaryStage 2: Progression Free Survival (PFS)

PFS was defined as the time from the date of randomization until first observation of objective progressive disease as defined by RECIST v1.1 or death from any cause, whichever comes first. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a patient does not have a complete baseline disease assessment, then the PFS time will be censored at the randomization date, regardless of whether or not objectively determined disease progression or death has been observed for the patient; otherwise, if a patient is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time will be censored at the last complete objective progression-free disease assessment date.

Time frame:
Baseline to Measured Progressive Disease or Death Due to Any Cause (Up to 6 Months)
Reported as:
Median · Months
Stage 2: Progression Free Survival (PFS)
Months200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Stage 2: Progression Free Survival (PFS)1.68 (1.35 to 1.84)1.81 (1.28 to 1.91)3.25 (1.05 to 5.65)
Statistical analysis
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Log Rank · p = 0.0085
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Log Rank · p = 0.0123
SecondaryStage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR

Objective response rate (ORR) is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Up to 6 Months)
Reported as:
Number · percentage of Participants
Stage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR
percentage of Participants200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Stage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR3 (0 to 8.9)0 (NA to NA)3 (0 to 8.9)
Statistical analysis
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Cochran-Mantel-Haenszel · p = 1
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Cochran-Mantel-Haenszel · p = 0.3017
SecondaryStage 1: Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib and Its Metabolites (LSN2839567 (M2), LSN3106726 (M20))

Mean steady state exposure was reported as measured by maximum observed plasma concentration (Cmax).

Time frame:
Cycle(C)1 Day(D)14: 0 hour(h),0.5h,1h,2h,4h,6h,8h post dose
Reported as:
Geometric mean · Nanogram per Millilitre (ng/mL)
Stage 1: Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib and Its Metabolites (LSN2839567 (M2), LSN3106726 (M20))
Nanogram per Millilitre (ng/mL)150mg Abemaciclib + 150mg Galunisertib
Abemaciclib356 ± 137
LSN2839567 (M2)85.1 ± 66
LSN3106726 (M20)153 ± 58
SecondaryStage 1: PK: Area Under the Curve (AUC) (AUC[Tau]) of LY3023414
Time frame:
Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)

No measurements were reported for this outcome.

SecondaryStage 1: PK: Maximum Concentration (Cmax) at Steady State of LY3023414
Time frame:
Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)

No measurements were reported for this outcome.

SecondaryStage 2: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD
Time frame:
Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)

No measurements were reported for this outcome.

SecondaryStage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months

Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD ≥6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

Time frame:
Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 6 Months)
Reported as:
Number · percentage of participants
Stage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months
percentage of participants200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Stage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months3 (0 to 8.9)0 (0 to 0)3 (0 to 8.9)
Statistical analysis
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Cochran-Mantel-Haenszel · p = 1
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Cochran-Mantel-Haenszel · p = 0.3017
SecondaryStage 2: Duration of Response (DoR)
Time frame:
Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 6 Months)

No measurements were reported for this outcome.

SecondaryStage 2: Overall Survival (OS)

OS duration is measured from the date of randomization to the date of death from any cause. for participants who is not known to have died as of the data-inclusion cutoff date, OS was censored at the last known alive date. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

Time frame:
Baseline to Death from Any Cause (Up to 10 Months)
Reported as:
Median · Months
Stage 2: Overall Survival (OS)
Months200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Stage 2: Overall Survival (OS)2.71 (1.97 to 5.36)3.29 (1.97 to 5.03)NA (2.53 to NA)
Statistical analysis
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Log Rank · p = 0.1938 · Hazard ratio (hr): 1.600 · 95% CI 0.782 to 3.272
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Log Rank · p = 0.2477 · Hazard ratio (hr): 1.533 · 95% CI 0.746 to 3.150
SecondaryStage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level

No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

Time frame:
Baseline, 6 Months
Reported as:
Mean · U/mL
Stage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level
U/mL200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Stage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level4281.53 ± 8177.893225.29 ± 5730.25-501.17 ± 7198.70
SecondaryStage 2: Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)

mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, and enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours, and typical completion time for this instrument is less than 5 minutes. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

Time frame:
Baseline, 6 Months
Reported as:
Least squares mean · score on a scale
Stage 2: Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
score on a scale200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Pain at its Worst in Last 24 hours0.63 ± 0.47-0.33 ± 0.55-0.02 ± 0.57
Pain at its Least in Last 24 hours0.86 ± 0.420.18 ± 0.490.39 ± 0.51
Pain on the Average0.62 ± 0.45-0.03 ± 0.51-0.07 ± 0.53
Pain Right Now0.38 ± 0.340.34 ± 0.59-0.38 ± 0.61
Pain Interfered General Activity0.64 ± 0.470.07 ± 0.550.22 ± 0.57
Pain Interfered with Mood0.54 ± 0.410.28 ± 0.480.60 ± 0.50
Pain Interfered Walking Ability0.05 ± 0.550.83 ± 0.640.19 ± 0.67
Pain Interfered with Normal Work1.07 ± 0.510.66 ± 0.590.19 ± 0.61
Pain Interfered with Relations0.39 ± 0.520.67 ± 0.610.26 ± 0.63
Pain Interfered with Sleep0.19 ± 0.530.34 ± 0.61-0.56 ± 0.65
Pain Interfered Enjoyment of Life0.69 ± 0.620.39 ± 0.72-0.13 ± 0.75
BPI Mean Pain Interference Score0.55 ± 0.440.50 ± 0.510.05 ± 0.54
Statistical analysis
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.383 · Lsmean difference: 0.65 · 95% CI -0.84 to 2.13
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.692 · Lsmean difference: -0.31 · 95% CI -1.91 to 1.28
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.469 · Lsmean difference: 0.48 · 95% CI -0.85 to 1.80
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.776 · Lsmean difference: -0.20 · 95% CI -1.62 to 1.22
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.328 · Lsmean difference: 0.69 · 95% CI -0.72 to 2.11
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.954 · Lsmean difference: 0.04 · 95% CI -1.45 to 1.54
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.350 · Lsmean difference: 0.75 · 95% CI -0.85 to 2.36
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.405 · Lsmean difference: 0.72 · 95% CI -1.01 to 2.44
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.565 · Lsmean difference: 0.43 · 95% CI -1.06 to 1.91
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.848 · Lsmean difference: -0.15 · 95% CI -1.74 to 1.43
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.928 · Lsmean difference: -0.06 · 95% CI -1.37 to 1.25
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.650 · Lsmean difference: -0.32 · 95% CI -1.71 to 1.08
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.865 · Lsmean difference: -0.15 · 95% CI -1.89 to 1.60
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.497 · Lsmean difference: 0.63 · 95% CI -1.23 to 2.50
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.272 · Lsmean difference: 0.89 · 95% CI -0.72 to 2.50
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.583 · Lsmean difference: 0.47 · 95% CI -1.25 to 2.19
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.876 · Lsmean difference: 0.13 · 95% CI -1.53 to 1.79
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.644 · Lsmean difference: 0.41 · 95% CI -1.37 to 2.19
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.384 · Lsmean difference: 0.75 · 95% CI -0.97 to 2.48
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.318 · Lsmean difference: 0.90 · 95% CI -0.90 to 2.71
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.407 · Lsmean difference: 0.81 · 95% CI -1.15 to 2.78
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.620 · Lsmean difference: 0.52 · 95% CI -1.58 to 2.62
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.475 · Lsmean difference: 0.50 · 95% CI -0.90 to 1.91
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.540 · Lsmean difference: 0.46 · 95% CI -1.04 to 1.96
SecondaryStage 2: Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

Time frame:
Baseline, 6 Months
Reported as:
Least squares mean · units on a scale
Stage 2: Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
units on a scale200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
Global Health Status-6.21 ± 3.87-4.82 ± 4.50-2.40 ± 4.64
Functional Scales: Physical Functioning-14.44 ± 4.40-11.65 ± 5.12-5.42 ± 5.12
Functional Scales: Role Functioning-17.09 ± 6.17-18.05 ± 7.32-17.10 ± 7.36
Functional Scales: Emotional Functioning-4.89 ± 4.49-0.63 ± 5.222.06 ± 5.41
Functional Scales: Cognitive Functioning-10.43 ± 4.10-8.39 ± 4.77-5.18 ± 4.95
Functional Scale: Social Functioning-21.12 ± 4.90-17.09 ± 5.72-2.00 ± 5.95
Symptom Scales: Fatigue14.13 ± 4.9214.90 ± 5.735.64 ± 5.71
Symptom Scales: Nausea and Vomiting7.98 ± 5.579.42 ± 6.4711.88 ± 6.50
Symptom Scales: Pain9.79 ± 5.632.68 ± 6.615.43 ± 6.62
Symptom Scale: Dysopnea0.35 ± 5.4811.19 ± 6.38-4.51 ± 6.36
Symptom Scale: Insomnia-5.19 ± 5.171.83 ± 6.01-6.71 ± 6.05
Symptom Scale: Appetite Loss12.54 ± 5.7915.32 ± 6.779.51 ± 7.30
Symptom Scale: Constipation2.96 ± 5.95-6.51 ± 6.9612.93 ± 7.15
Symptom Scale: Diarrhoea15.71 ± 6.7626.28 ± 7.8320.51 ± 7.98
Symptom Scale: Financial difficulties3.96 ± 4.822.45 ± 5.68-3.30 ± 5.87
Statistical analysis
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.818 · Lsmean difference: -1.39 · 95% CI -13.46 to 10.68
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.533 · Lsmean difference: -3.80 · 95% CI -16.03 to 8.42
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.681 · Lsmean difference: -2.79 · 95% CI -16.40 to 10.82
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.189 · Lsmean difference: -9.02 · 95% CI -22.63 to 4.59
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.921 · Lsmean difference: 0.96 · 95% CI -18.29 to 20.21
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.999 · Lsmean difference: 0.01 · 95% CI -19.40 to 19.42
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.541 · Lsmean difference: -4.26 · 95% CI -18.20 to 9.68
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.330 · Lsmean difference: -6.95 · 95% CI -21.17 to 7.27
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.747 · Lsmean difference: -2.04 · 95% CI -14.74 to 10.66
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.419 · Lsmean difference: -5.25 · 95% CI -18.22 to 7.73
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.596 · Lsmean difference: -4.02 · 95% CI -19.23 to 11.19
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.017 · Lsmean difference: -19.12 · 95% CI -34.68 to -3.55
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.919 (Social Scales: Fatigue) · Lsmean difference: -0.77 · 95% CI -16.03 to 14.49
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.267 · Lsmean difference: 8.48 · 95% CI -6.72 to 23.69
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.866 · Lsmean difference: -1.45 · 95% CI -18.66 to 15.77
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.652 · Lsmean difference: -3.90 · 95% CI -21.23 to 13.43
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.417 · Lsmean difference: 7.11 · 95% CI -10.39 to 24.60
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.618 · Lsmean difference: 4.36 · 95% CI -13.16 to 21.89
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.206 · Lsmean difference: -10.84 · 95% CI -27.85 to 6.18
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.566 · Lsmean difference: 4.86 · 95% CI -12.08 to 21.80
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.380 · Lsmean difference: -7.02 · 95% CI -23.01 to 8.96
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.850 · Lsmean difference: 1.52 · 95% CI -14.60 to 17.64
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.756 · Lsmean difference: -2.79 · 95% CI -20.78 to 15.21
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.747 · Lsmean difference: 3.02 · 95% CI -15.77 to 21.82
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.311 · Lsmean difference: 9.47 · 95% CI -9.16 to 28.09
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.290 · Lsmean difference: -9.97 · 95% CI -28.75 to 8.80
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.323 · Lsmean difference: -10.57 · 95% CI -31.93 to 10.78
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.651 · Lsmean difference: -4.80 · 95% CI -26.08 to 16.48
  • 200mg Abemaciclib vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.841 · Lsmean difference: 1.51 · 95% CI -13.57 to 16.59
  • 150mg Abemaciclib + 150mg LY3023414 vs Gemcitabine or Capecitabine · Mixed Models Analysis · p = 0.344 · Lsmean difference: 7.26 · 95% CI -8.03 to 22.54
SecondaryStage 1: PK: Steady State Trough Pre Dose Concentration of LY3023414

Mean steady state exposure was reported by trough pre-dose plasma concentrations.

Time frame:
C2D1: 0h, C3D1: 0h, C4D1: 0h
Reported as:
Geometric mean · ng/mL
Stage 1: PK: Steady State Trough Pre Dose Concentration of LY3023414
ng/mL150mg Abemaciclib + 150mg LY3023414
Stage 1: PK: Steady State Trough Pre Dose Concentration of LY302341427.3 ± 450
SecondaryStage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose

Mean single dose exposure was reported by plasma concentrations collected approximately 2 hours post-dose.

Time frame:
C1D1: 2h Post dose
Reported as:
Geometric mean · ng/mL
Stage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose
ng/mL150mg Abemaciclib + 150mg LY3023414
Stage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose518 ± 67

Adverse events

Collected over Up to 30 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150mg Abemaciclib + 150mg Galunisertib (Safety Lead - In)5/7 (71.4%)4/7 (57.1%)7/7 (100%)
200mg Abemaciclib22/32 (68.8%)17/32 (53.1%)30/32 (93.8%)
150mg Abemaciclib + 150mg LY302341421/33 (63.6%)18/33 (54.5%)33/33 (100%)
Gemcitabine or Capecitabine12/26 (46.2%)15/26 (57.7%)25/26 (96.2%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
Event150mg Abemaciclib + 150mg Galunisertib (Safety Lead - In)200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
VomitingGastrointestinal disorders0/71/322/334/26
AnaemiaBlood and lymphatic system disorders1/70/321/330/26
Gastric ulcer haemorrhageGastrointestinal disorders1/70/320/330/26
AstheniaGeneral disorders1/70/320/330/26
FatigueGeneral disorders1/71/321/330/26
Systemic inflammatory response syndromeGeneral disorders1/70/320/330/26
SepsisInfections and infestations1/71/321/330/26
UrosepsisInfections and infestations1/70/320/330/26
Platelet count decreasedInvestigations1/70/321/330/26
White blood cell count decreasedInvestigations1/70/320/330/26
Most frequent other events
Showing 10 of 104
Most frequent other events
Event150mg Abemaciclib + 150mg Galunisertib (Safety Lead - In)200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or Capecitabine
NauseaGastrointestinal disorders5/79/3215/339/26
DiarrhoeaGastrointestinal disorders4/712/3217/338/26
FatigueGeneral disorders4/716/3217/3311/26
HyponatraemiaMetabolism and nutrition disorders4/71/323/331/26
VomitingGastrointestinal disorders2/710/3215/336/26
AnaemiaBlood and lymphatic system disorders3/710/326/3311/26
Decreased appetiteMetabolism and nutrition disorders3/79/328/338/26
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/70/322/3310/26
StomatitisGastrointestinal disorders0/70/3212/336/26
Platelet count decreasedInvestigations0/710/325/334/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in)200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or CapecitabineTotal
Mean65.29 ± 6.9961.09 ± 7.8362.52 ± 8.9766.85 ± 7.6163.40 ± 8.34
Sex: Female, Male
Sex: Female, Male(Participants)150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in)200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or CapecitabineTotal
Female418161957
Male315171449
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in)200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or CapecitabineTotal
Hispanic or Latino02439
Not Hispanic or Latino730282489
Unknown or Not Reported01168
Race (NIH/OMB)
Race (NIH/OMB)(Participants)150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in)200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or CapecitabineTotal
American Indian or Alaska Native00000
Asian075416
Native Hawaiian or Other Pacific Islander00000
Black or African American00134
White726262584
More than one race00000
Unknown or Not Reported00112
Region of Enrollment
Region of Enrollment(Participants)150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in)200mg Abemaciclib150mg Abemaciclib + 150mg LY3023414Gemcitabine or CapecitabineTotal
Belgium086519
United States7810833
Taiwan074314
United Kingdom01001
Israel024511
Australia01135
France01168
Spain057315
08

Study locations

32 sites
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Illinois CancerCare
    Peoria, Illinois 61615, United States
  • Research Medical Center
    Kansas City, Missouri 64132, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756-0001, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • Seattle Cancer Care Alliance
    Olympia, Washington 98109, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • University of Wisconsin-Madison Hospital and Health Clinic
    Madison, Wisconsin 53792-4108, United States
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Blacktown, 2148, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sydney, 2010, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1200, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edegem, 2650, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Wilrijk, 2610, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69373, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75014, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pessac, 33604, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haifa, 3109601, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ramat Gan, 5262000, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tel Aviv, 6423906, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08036, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hospitalet de Llobregat, 08908, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28040, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Malaga, 29010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tainan, 70403, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei city, 10048, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 11217, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, NW1 2BU, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement. More information provided by Eli Lilly and Company

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2018, 15 months.

Results were first posted in Jun 2019, 1 year 2 months after primary completion.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 15 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2016
First posted
Dec 5, 2016
StartActual
Jan 12, 2017
Primary completionActual
Apr 20, 2018
CompletionActual
Nov 9, 2018
Results first posted
Jun 25, 2019
Last update
Nov 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02981342
Responsible party
Sponsor
First posted
Dec 5, 2016
Start date
Jan 12, 2017
Primary completion
Apr 20, 2018
Completion
Nov 9, 2018
Results posted
Jun 25, 2019
Last update
Nov 20, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Gemcitabine · Capecitabine

Start the discussion